InvestSMART

AdAlta Limited (ASX:1AD)

ALERT: Price-sensitive ASX Announcement for 1AD
Current share price for 1AD : $0.004 -0.001 (-12.50%)+
Announcement
Release
27 Mar 2026 9:46AM
Price at Release
$0.004
Full Release
download
Summary
AdAlta Limited, through its subsidiary AdCella Pty Ltd, held its first Joint Development Committee (JDC) meeting with the Shanghai Cell Therapy Group to advance their BZDS1901 CAR-T cell therapy program for treating advanced mesothelioma and other solid cancers. The meeting marked a shift from planning to execution, identifying opportunities to accelerate technology transfer to Australia by six months, thus reducing timelines and regulatory risks. The engagement with the US FDA is planned in two stages to improve regulatory feedback, with the first meeting providing early clarity on requirements and the second confirming the acceptability of AdCella's manufacturing process. The collaboration aims to integrate Asian T cell therapy development with Australia's clinical and manufacturing capabilities. Key outcomes include the potential for manufacturing technology transfer and improved FDA engagement. The JDC meeting also saw the completion of dosing for Cohort 1 of a China-based trial, with updated results pending.
Key Points
  • First Joint Development Committee meeting held for BZDS1901
  • Transition from planning to joint execution
  • Potential acceleration of manufacturing transfer to Australia by six months
  • Two-stage US FDA engagement strategy planned
  • Completion of Cohort 1 dosing for China Investigator Initiated Trial
  • Integration of Asian T cell therapy development with Australian capabilities
  • AdAlta Limited operates in the biotechnology sector focusing on cellular immunotherapies for solid cancers
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.